Bright Minds Biosciences Inc. (CSE:DRUG)
Canada · Delayed Price · Currency is CAD | Market Cap | 638.43M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.92M |
| Shares Out | 7.79M |
| EPS (ttm) | -1.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Average Volume | 679 |
| Open | 81.73 |
| Previous Close | 82.00 |
| Day's Range | 81.73 - 81.73 |
| 52-Week Range | 33.01 - 96.50 |
| Beta | -0.33 |
| RSI | 53.29 |
| Earnings Date | Dec 29, 2025 |
About Bright Minds Biosciences
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboratio... [Read more]
Financial Performance
Financial StatementsNews
Why Bright Minds Biosciences Stock Topped the Market on Monday
The company isn't wasting any time drafting seasoned professionals to help it develop medication for a rare genetic disorder.
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company's PWS program, which w...
Sio Capital Management, LLC Reduces Stake in Bright Minds Biosciences Inc
Sio Capital Management, LLC Reduces Stake in Bright Minds Biosciences Inc
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prad...
Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable
Bright Minds Biosciences Inc. (DRUG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks tha...
Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade
The consensus price target hints at an 81.3% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward tren...
Bright Minds Biosciences (DRUG) Maintains 'Buy' Rating with $85 Price Target | DRUG Stock News
Bright Minds Biosciences (DRUG) Maintains 'Buy' Rating with $85 Price Target | DRUG Stock News
Large Patient Population Is Key Driver For Bright Minds' Growth
BTIG initiated coverage on Bright Minds Biosciences Inc. (NASDAQ: DRUG), a clinical-stage company focused on neurological and psychiatric disorders . Investment in Bright Minds is based on the expect...
Bright Minds Biosciences (DRUG) Launches $100 Million ATM Offering
Bright Minds Biosciences (DRUG) Launches $100 Million ATM Offering
BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING
VANCOUVER, BC , Sept. 4, 2025 /CNW/ - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (" Bright Minds " or the " Company ") announces that it has entered into an equity distribution agreeme...
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025
- Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D'Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD -
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside
Chardan Research initiated coverage on Wednesday of Bright Minds Biosciences Inc. DRUG, an epilepsy drug developer.
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside
Chardan Research initiated coverage on Wednesday of Bright Minds Biosciences Inc. (NASDAQ: DRUG), an epilepsy drug developer . The company’s lead product, BMB-101, is a novel scaffold 5-HT2C Gq-prote...
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selec...
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025
COMMODORE CAPITAL LP's Strategic Acquisition in Bright Minds Biosciences Inc
COMMODORE CAPITAL LP's Strategic Acquisition in Bright Minds Biosciences Inc
Sio Capital Management, LLC Acquires Significant Stake in Bright Minds Biosciences Inc
Sio Capital Management, LLC Acquires Significant Stake in Bright Minds Biosciences Inc
JANUS HENDERSON GROUP PLC Acquires Shares in Bright Minds Biosciences Inc
JANUS HENDERSON GROUP PLC Acquires Shares in Bright Minds Biosciences Inc
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101
Bright Minds Biosciences names Stephen Collins as chief medical officer
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Brig...
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that further to its news release of ...
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the most...
Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
LONDON--(BUSINESS WIRE)---- $DRUG #Nasdaq--Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demons...